Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

Source The Motley Fool

Key Points

  • Merck's two most important growth drivers are encountering headwinds now.

  • While they are manageable, the company's mid-term prospects aren't strong.

  • 10 stocks we like better than Merck ›

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a leading pharmaceutical company, pull it off?

Doctor and patient talking.

Image source: Getty Images.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Merck is facing challenges

Merck's biggest growth drivers are cancer drug Keytruda and its HPV vaccine franchise, Gardasil and Gardasil 9. However, both are facing issues.

Keytruda will experience a patent cliff by 2028, inviting biosimilar competition that will likely erode its sales. And even beyond that, several medicines in development are looking to challenge Keytruda's dominance. Meanwhile, sales of Gardasil and Gardasil 9 have declined this year largely due to lower demand in China.

In the second quarter, Merck's revenue decreased by 2% year over year to $15.8 billion. These headwinds (and others) explain why Merck's shares have significantly lagged the market this year.

Don't bet on it

Merck can navigate these challenges. The company recently earned approval for a subcutaneous version of Keytruda. This newer formulation will benefit from patent protection beyond 2028 while taking on most of the older version's indications.

Subcutaneous Keytruda proved just as effective while reducing patient monitoring and prep time significantly for physicians, making it a better option in many cases. And regarding Gardasil and Gardasil 9's issues, Merck is working those out and expects the vaccines' sales to rebound and grow at a good clip through the next few years.

Further, the drugmaker has newer approvals, such as Winrevair for treating pulmonary arterial hypertension. Even so, Merck's challenges will weigh on the stock enough to make it hard for the company to beat the market through 2030 -- let alone deliver an outrageous CAGR of 38% it needs to turn $10,000 into $50,000 by then.

Is Merck stock a buy? For long-term, dividend-seeking investors, the drugmaker still looks attractive. For investors looking for a CAGR of 38% through 2030, it's not a good choice.

Should you invest $1,000 in Merck right now?

Before you buy stock in Merck, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $657,979!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,746!*

Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 187% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of October 13, 2025

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
TSMC Q3 Earnings Preview: Record Revenue Is a Lock, but an Upgraded Outlook Could Be the Real CatalystGlobal semiconductor foundry leader Taiwan Semiconductor Manufacturing Company (TSMC, TSM) will report its Q3 2025 earnings on Thursday, October 16, before U.S. markets open.
Author  TradingKey
6 hours ago
Global semiconductor foundry leader Taiwan Semiconductor Manufacturing Company (TSMC, TSM) will report its Q3 2025 earnings on Thursday, October 16, before U.S. markets open.
placeholder
Intel Downgraded by BofA and HSBC: Is a 50% Monthly Surge Overly Optimistic?HSBC has lowered Intel's rating from "Hold" to "Reduce," and Bank of America has adjusted its rating from "Neutral" to "Underperform".
Author  TradingKey
6 hours ago
HSBC has lowered Intel's rating from "Hold" to "Reduce," and Bank of America has adjusted its rating from "Neutral" to "Underperform".
placeholder
Powell Speech Preview: Will Fed Chair confirm two more rate cuts?With the US government shutdown causing key data releases to be postponed, Powell's comments could influence the US Dollar's valuation in the near term.
Author  FXStreet
6 hours ago
With the US government shutdown causing key data releases to be postponed, Powell's comments could influence the US Dollar's valuation in the near term.
placeholder
Aave Price Forecast: AAVE slips below $260 as on-chain metrics turn bearishAave (AAVE) price trade below $260 at the time of writing on Tuesday as the token faces weakness around its key resistance zone.
Author  FXStreet
7 hours ago
Aave (AAVE) price trade below $260 at the time of writing on Tuesday as the token faces weakness around its key resistance zone.
placeholder
WTI Oil drops to the $58.00 area as global trade fears resurfaceThe US benchmark West Texas Intermediate Oil has lost nearly $1 per barrel on Tuesday, retreating to levels near $58.00.
Author  FXStreet
7 hours ago
The US benchmark West Texas Intermediate Oil has lost nearly $1 per barrel on Tuesday, retreating to levels near $58.00.
goTop
quote